GT Biopharma, Inc 8-K, filed May 19, 2021
GT Biopharma, Inc. (GTBP)
8-K
2021-05-19
For: 2021-05-19
View Original
Added on
April 10, 2026
About this 8-K
GT Biopharma, Inc filed this 8-K on May 19, 2021.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
Report:
(Date
of earliest event reported)
May 19, 2021
____________________________
GT Biopharma, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other Jurisdiction of Incorporation)
|
1-40023
(Commission
File Number)
|
|
94-1620407
(IRS Employer Identification No.)
|
|
|
9350 Wilshire Blvd., Suite 203
Beverly Hills, CA 90212
(Address
of Principal Executive Offices and zip code)
|
|
(800) 304-9888
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12(b) under the Exchange
Act (17 CFR 240.14a-12(b))
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each Class
|
Trading
Symbol(s)
|
Name of
each Exchange on which registered
|
|
Common
stock, $0.001 par value
|
GTBP
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR 240.12b-2).
Emerging growth
company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01
Regulation FD Disclosure.
On May
19, 2021, the Registrant’s will present information regarding
the Registrant’s business via teleconference. The
Registrant’s Investor Day presentation for such
teleconference as of May 19, 2021 is filed as Exhibit 99.1 and is
incorporated herein by reference.
Item
9.01
Financial
Statements and Exhibits.
(d)
Exhibits.
GT Biopharma, Inc.
Investor Day Presentation as of May 19, 2021.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
GT
BIOPHARMA, INC.
|
|
|
|
|
|
|
|
|
Date: May 19,
2021
|
By:
|
/s/
Michael
Handelman
|
|
|
|
|
Michael
Handelman
|
|
|
|
|
Chief Financial
Officer
|
|
Exhibit
99.1
